Patents by Inventor Yair Sapir

Yair Sapir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSESSMENT OF CEACAM1 EXPRESSION ON TUMOR INFILTRATING LYMPHOCYTES
    Publication number: 20240092934
    Abstract: Provided are methods and compositions comprising antibodies capable of specific binding to human CEACAM1 molecules, for treating and diagnosing cancer as well as assessing CEACAM1 expression in tumor infiltrating immune cells (TILs) in a biological sample obtained from a [cancer] subject.
    Type: Application
    Filed: November 24, 2023
    Publication date: March 21, 2024
    Applicant: FAMEWAVE LTD.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Rona ORTENBERG, Jacob SCHACHTER, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
    Patent number: 11891453
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 6, 2024
    Assignee: FAMEWAVE LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF
    Publication number: 20240010706
    Abstract: Chimeric molecules comprising a fibrinogen-related domain (FRED) from human fibrinogen-like protein 2 (FGL2) are provided. Immunomodulatory pharmaceutical compositions comprising the chimeric molecules, as well as methods for reducing inflammation and treating autoimmune disease in a subject by administering the chimeric molecules or immunomodulatory pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 31, 2021
    Publication date: January 11, 2024
    Inventors: Ilana MANDEL, Motti HAKIM, Zohar KEREN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE
  • Humanized antibodies against CEACAM1
    Patent number: 11866509
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 9, 2024
    Assignee: FAMEWAVE LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY
    Publication number: 20230221325
    Abstract: Methods of determining suitability of a subject suffering from cancer or at risk of cancer relapse to receive treatment comprising an agent that reduces sCD28 levels are provided. Methods of treating a subject suffering from cancer or at risk of cancer relapse comprising administering an anti-PD-1/PD-L1 immunotherapy, measuring soluble CD28 levels in a subject, and administering an agent that reduces sCD28 levels to a subject whose sCD28 levels increased are also provided.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 13, 2023
    Inventors: Anna FRIDMAN-DROR, Tal GABAY, Orit SHILOVIZKY, Dror ALISHEKEVITZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN, Motti HAKIM
  • SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY
    Publication number: 20230144459
    Abstract: Agents comprising at least two moieties separated by a linker, wherein a first moiety binds mCD28 on a surface of a cell and inhibits proteolytic cleavage of the mCD28 and wherein a second moiety increases stability of the first moiety are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.
    Type: Application
    Filed: March 11, 2021
    Publication date: May 11, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN, Lilach Chen ZELTSBURG, Ayala LEWKOWICZ
  • USE OF MMP INHIBITION
    Publication number: 20230041599
    Abstract: Methods of decreasing shedding of CD28, decreasing soluble CD28 levels, treating cancer and improving immunotherapies comprising inhibiting matrix metalloproteases are provided. Methods of producing agents for performance of the methods of the invention are also provided.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 9, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY
    Publication number: 20230035730
    Abstract: Methods of diagnosing and predicting cancer relapse comprising measuring soluble CD28 levels in a subject, wherein an increase in soluble CD28 is indicative of cancer relapse or imminent cancer relapse, are provided. Methods of determining response to PD-1/PD-L1 based immunotherapy in a subject in need thereof, comprising measuring sCD28 levels in a subject undergoing PD-1/PD-L1 based immunotherapy at at least two time points wherein a decrease indicates response and an increase indicates lack of response, are also provided.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 2, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Orit SHILOVIZKY, Dror ALISHEKEVITZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • Polynucleotides encoding humanized antibodies against CEACAM1
    Patent number: 11427647
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 30, 2022
    Assignee: FAMEWAVE LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • SMALL SHEDDING BLOCKING AGENTS
    Publication number: 20220169732
    Abstract: Agents that are less than 100 kilodaltons, bind a membranal immune receptor on a surface of a cell and inhibit proteolytic cleavage of the immune receptor are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.
    Type: Application
    Filed: March 12, 2020
    Publication date: June 2, 2022
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Dror ALISHEKEVITZ, Edna MEILIN, Ilana MANDEL, Tehila BEN-MOSHE, Avidor SHULMAN, Yair SAPIR
  • A METHOD FOR IMMUNOSUPPRESSION
    Publication number: 20220153845
    Abstract: The present invention, in some embodiments thereof, is directed to a method for suppressing an immune response in a subject, including administering to the subject a therapeutically effective amount of an agent having specific binding affinity to a soluble immune receptor.
    Type: Application
    Filed: March 12, 2020
    Publication date: May 19, 2022
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Edna MEILIN, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20220153836
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 19, 2022
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20220048991
    Abstract: The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 17, 2022
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • Antibodies against ILT2
    Patent number: 11236162
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 1, 2022
    Assignee: Biond Biologies Ltd.
    Inventors: Ilana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20210277112
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 9, 2021
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)
    Publication number: 20210070884
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 11, 2021
    Applicant: Famewave Ltd.
    Inventors: Gal MARKEL, Tehila BEN MOSHE, Yair SAPIR, Ilana MANDEL, Jacob SCHACHTER, Rona ORTENBERG
  • METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
    Publication number: 20210047411
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Application
    Filed: March 14, 2019
    Publication date: February 18, 2021
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Dana HAVES ZIV, Edna MEILIN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE, Ilana MANDEL
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20200277398
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 3, 2020
    Applicant: Famewave Ltd.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20200216557
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: December 2, 2019
    Publication date: July 9, 2020
    Applicant: Famewave Ltd.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • Humanized antibodies against CEACAM1
    Patent number: 10550196
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 4, 2020
    Assignee: Famewave Ltd.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones